Sustainability of Rituximab Therapy in Different Treatment Strategies: Results of a 3-Year Followup of a German Biologics Register

Arthritis Care and Research

Volumn 66, Issue 11, 2014, Pages 1627-1633

  Richter, Adrian ^a   Strangfeld, Anja ^a   Herzer, Peter ^b   Wilden, Elke ^c   Bussmann, Arnold ^d   Listing, Joachim ^a   Zink, Angela ^e  

^a German Rheumatism Research Center   (Germany)

^b Scientific Advisory Board   (Germany)

^c German Rheumatism Research Center and Charité University Medicine ^*  (Germany)

^d Ambulante Reha am Krankenhaus GmbH   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; LEFLUNOMIDE; METHOTREXATE; RHEUMATOID FACTOR; RITUXIMAB;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DAS28; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; OFF LABEL DRUG USE; PATIENT COMPLIANCE; PATIENT DROPOUT; PROSPECTIVE STUDY; RETREATMENT; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

EID: 85007158185     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22327     Document Type: Article

References (22)

1. Bokarewa M, Lindholm C, Zendjanchi K, Nadali M, Tarkowski A. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/ anti-TNF therapy. Scand J Immunol 2007;66:476–83.
2. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572–81.
3. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group.Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793–806.
4. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dorner T, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:909–20.
5. Narvaez J, Diaz-Torne C, Ruiz JM, Hernandez MV, Torrente-Segarra V, Ros S, et al. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 2011;41:401–5.
6. Solau-Gervais E, Prudhomme C, Philippe P, Duhamel A, Dupont-Creteur C, Legrand JL, et al. Efficacy of rituximab in the treatment of rheumatoid arthritis: influence of serologic status, coprescription of methotrexate and prior TNF-α inhibitors exposure. Joint Bone Spine 2012;79:281–4.
7. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis 2012;71:374–7.
8. Smolen JS, Aletaha D, Keystone E. Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction? [review].Arthritis Rheum 2005;52:2975–83.
9. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
10. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
11. Lautenschlaeger J, Mau W, Kohlmann T, Raspe HH, Struve F, Bruckle W, et al. Comparative evaluation of a German version of the Health Assessment Questionnaire and the Hannover Functional Capacity Questionnaire. Z Rheumatol 1997;56:144–55. In German.
12. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. JAMA 2009;301:737–44.
13. Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?Ann Rheum Dis 2011;70:1914–20.
14. Therneau T, Grambsch P.Modeling survival data: extending the Cox model.New York:Springer-Verlag; 2000.
15. Wei LJ. The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis. Stat Med 1992;11:1871–9.
16. Fitzmaurice GM, Laird NM, Ware JH.Applied longitudinal analysis.Hoboken (NJ):Wiley-Interscience; 2004.
17. Raghunathan T, Lepkowski JM, Van Hoewyk J, Solenberger P. A multivariate technique for multiply imputing missing values: using a sequence of regression models. Survey Methodol 2001;27:85–95.
18. Burnham KP, Anderson DR. Multimodel inference: understanding AIC and BIC in model selection. Sociol Methods Res 2004;33:261–304.
19. R Development Core Team.R: a language and environment for statistical computing.Vienna:R Foundation for Statistical Computing; 2005.
20. Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM, and the British Society for Rheumatology Biologics Register.Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register. J Rheumatol 2012;39:240–6.
21. Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012;71:1134–42.
22. Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Lei G, et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 2013;72:329–36.